FDA — authorised 1 May 1953
- Application: NDA008845
- Marketing authorisation holder: HOSPIRA
- Local brand name: QUELICIN PRESERVATIVE FREE
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 SUCCINYLCHOLINE CHLORIDE in United States
FDA authorised SUCCINYLCHOLINE CHLORIDE on 1 May 1953 · 1,334 US adverse-event reports
Marketing authorisations
FDA — authorised 20 September 1972
- Application: ANDA080997
- Marketing authorisation holder: ORGANON USA INC
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 4 May 2018
- Application: ANDA209467
- Marketing authorisation holder: ZYDUS PHARMS
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 16 November 2018
- Application: ANDA211432
- Marketing authorisation holder: AMNEAL
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 2 August 2019
- Application: ANDA210698
- Marketing authorisation holder: DR REDDYS
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 22 May 2020
- Application: ANDA214308
- Marketing authorisation holder: REGCON HOLDINGS
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 12 June 2020
- Application: ANDA213229
- Marketing authorisation holder: HIKMA
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 27 October 2020
- Application: ANDA213552
- Marketing authorisation holder: NEXUS
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 20 November 2020
- Application: ANDA211346
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 24 November 2020
- Application: ANDA214879
- Marketing authorisation holder: MICRO LABS
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 21 December 2020
- Application: ANDA214491
- Marketing authorisation holder: DEVA HOLDING AS
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 20 August 2021
- Application: NDA215143
- Marketing authorisation holder: HIKMA
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: SOLUTION — INTRAMUSCULAR, INTRAVENOUS
- Status: approved
FDA — authorised 7 February 2022
- Application: ANDA216003
- Marketing authorisation holder: BE PHARMS
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 2 February 2023
- Application: ANDA216127
- Marketing authorisation holder: MANKIND PHARMA
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 16 October 2023
- Application: ANDA217808
- Marketing authorisation holder: EUGIA PHARMA
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 9 July 2024
- Application: ANDA217873
- Marketing authorisation holder: STERISCIENCE
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: SOLUTION — INTRAMUSCULAR, INTRAVENOUS
- Status: approved
FDA — authorised 24 September 2024
- Application: ANDA218878
- Marketing authorisation holder: BAXTER HLTHCARE CORP
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 February 2025
- Application: ANDA217884
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: SOLUTION — INTRAMUSCULAR, INTRAVENOUS
- Status: approved
FDA — authorised 21 February 2025
- Application: ANDA217885
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: SUCCINYLCHOLINE CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Status: approved
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 1,334
Most-reported reactions
- Drug Ineffective — 236 reports (17.69%)
- Hypotension — 172 reports (12.89%)
- Cardiac Arrest — 164 reports (12.29%)
- Anaphylactic Shock — 139 reports (10.42%)
- Drug Interaction — 122 reports (9.15%)
- Anaphylactic Reaction — 115 reports (8.62%)
- Renal Failure — 99 reports (7.42%)
- Renal Impairment — 97 reports (7.27%)
- Pain — 96 reports (7.2%)
- Hyperthermia Malignant — 94 reports (7.05%)
SUCCINYLCHOLINE CHLORIDE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is SUCCINYLCHOLINE CHLORIDE approved in United States?
Yes. FDA authorised it on 1 May 1953; FDA authorised it on 20 September 1972; FDA authorised it on 4 May 2018.
Who is the marketing authorisation holder for SUCCINYLCHOLINE CHLORIDE in United States?
HOSPIRA holds the US marketing authorisation.